对精神分裂症躯体健康问题的生活方式干预

doi:10.3969/j.issn.1006-7795.2019.05.007

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (5): 698-702.doi: 10.3969/j.issn.1006-7795.2019.05.007

• 临床心理研究进展与实践 • 上一篇下一篇

对精神分裂症躯体健康问题的生活方式干预

庄文旭, 张伟波, 朱有为, 朱益, 蔡军

上海交通大学医学院附属精神卫生中心疾病预防控制精神卫生分中心, 上海 200030

收稿日期:2019-07-04 出版日期:2019-09-21 发布日期:2019-12-16
通讯作者: 蔡军 E-mail:caijun533@163.com
基金资助:
上海市精神卫生中心医学青年人才启航培养计划（2017-QH-3），上海市卫生计生系统重要薄弱学科建设（2015ZB0405），上海市卫生和计划生育委员会科研课题（20164Y100）。

Lifestyle interventions for physical health conditions in patients with schizophrenia

Zhuang Wenxu, Zhang Weibo, Zhu Youwei, Zhu Yi, Cai Jun

Shanghai Municipal Center of Mental Disease Prevention and Control, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China

Received:2019-07-04 Online:2019-09-21 Published:2019-12-16
Supported by:
This study was supported by Qihang Project of Shanghai Mental Health Center(2017-QH-3),Shanghai Municipal Health and Family Planning Commission Key Developing Disciplines(2015ZB0405),Shanghai Municipal Health and Family Planning Commission Research Project(20164Y100).

摘要/Abstract

摘要： 精神分裂症患者的躯体健康问题突出，尤其是肥胖以及代谢、心血管相关疾病。生活方式干预是近年来被推荐的针对肥胖等问题的一种非药物干预方式，包括增加运动量和改善饮食习惯。整理近年来对精神分裂症患者进行生活方式干预的研究，发现运动锻炼结合饮食调整的行为方式干预对患者的体质量控制具有良好效果，对血压、血糖、腰臀比等指标也有一定效果。希望对我国的严重精神障碍社区管理治疗服务有所启示，关注精神分裂症患者的躯体健康问题并在社区康复中提供综合性的生活方式干预。

关键词: 精神分裂症, 代谢综合征, 行为干预

Abstract: The physical health problems in schizophrenia are prominent, especially obesity and metabolic and cardiovascular diseases. Lifestyle interventions including physical activity and dietary adjustment are recommended as non-drug interventions for obesity and other related medical conditions. The paper summarized recent studies on lifestyle intervention in patients with schizophrenia. It has been proved that lifestyle interventions have a significant effect on weight loss but a less obvious effects on blood pressure, glucose and waist-hip ratio control. It may shed light on correlation between physical health problems of patients with schizophrenia and the community management and treatment services of severe mental disorders in China. The influence of lifestyle interventions in the community rehabilitation on the physical health problems of patients with schizophrenia should be concerned.

Key words: schizophrenia, metabolic syndrome, behavioral intervention

中图分类号:

R749.3

庄文旭, 张伟波, 朱有为, 朱益, 蔡军. 对精神分裂症躯体健康问题的生活方式干预[J]. 首都医科大学学报, 2019, 40(5): 698-702.

Zhuang Wenxu, Zhang Weibo, Zhu Youwei, Zhu Yi, Cai Jun. Lifestyle interventions for physical health conditions in patients with schizophrenia[J]. Journal of Capital Medical University, 2019, 40(5): 698-702.

参考文献

[1] Hjorthøj C, Stürup A E, McGrath J J, et al. Years of potential life lost and life expectancy in schizophrenia:a systematic review and meta-analysis[J]. Lancet Psychiatry, 2017, 4(4):295-301.
[2] Dickerson F, Origoni A, Schroeder J, et al. Mortality in schizophrenia and bipolar disorder:clinical and serological predictors[J]. Schizophr Res, 2016, 170(1):177-183.
[3] Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the united states[J]. JAMA psychiatry, 2015, 72(12):1172-1181.
[4] Cooper S J, Reynolds G P, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment[J]. J Psychopharmacol,2016, 30(8):717-748.
[5] Vancampfort D, Stubbs B, Mitchell A J, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:a systematic review and meta-analysis[J]. World Psychiatry,2015,14(3):339-347.
[6] Andrade C. Cardiometabolic Risks in schizophrenia and directions for intervention, 1:magnitude and moderators of the problem[J]. J Clin Psychiatry,2016,77(7):e844-847.
[7] Webb V L, Wadden T A. Intensive lifestyle intervention for obesity:principles, practices, and results[J]. Gastroenterology, 2017, 152(7):1752-1764.
[8] Gorter K J, van de Laar F A, Janssen P G, et al. Diabetes:glycaemic control in type 2(drug treatments)[J]. BMJ Clin Evid, 2012,2012. pill:0609.
[9] Gay H C, Rao S G, Vaccarino V, et al. Effects of different dietary interventions on blood pressure:systematic review and meta-analysis of randomized controlled trials[J]. Hypertension, 2016, 67(4):733-739.
[10] Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients:office based strategies for primary care practitioners and endocrinologists[J]. Int J Endocrinol, 2015,2015:969182.
[11] Kuipers E, Yesufu-Udechuku A, Taylor C, et al. Management of psychosis and schizophrenia in adults:summary of updated NICE guidance[J]. BMJ, 2014, 348:g1173.
[12] Allison D B, Newcomer J W, Dunn A L, et al. Obesity among those with mental disorders:a National Institute of Mental Health meeting report[J]. Am J Prev Med, 2009, 36(4):341-350.
[13] Pallava A, Chadda R K, Sood M, et al. Metabolic syndrome in schizophrenia:A comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India[J]. Nord J Psychiatry, 2012, 66(3):215-221.
[14] Chaggar P S, Shaw S M, Williams S G. Effect of antipsychotic medications on glucose and lipid levels[J]. J Clin Pharmacol, 2011, 51(5):631-638.
[15] Kilbourne A M, Morden N E, Austin K, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders:identifying modifiable risk factors[J]. Gen Hosp Psychiatry, 2009, 31(6):555-563.
[16] Kilbourne A M, McCarthy J F, Post E P, et al. Access to and satisfaction with care comparing patients with and without serious mental illness[J]. Int J Psychiatry Med, 2006, 36(4):383-399.
[17] Peet M. Nutrition and schizophrenia:an epidemiological and clinical perspective[J]. Nutr Health, 2003, 17(3):211-219.
[18] Dickey B, Normand S L T, Weiss R D, et al. Medical morbidity, mental illness, and substance use disorders[J]. Psychiatr Serv, 2002, 53(7):861-867.
[19] Dipasquale S, Pariante C M, Dazzan P, et al. The dietary pattern of patients with schizophrenia:a systematic review[J]. J Psychiatr Res, 2013, 47(2):197-207.
[20] Daumit G L, Goldberg R W, Anthony C, et al. Physical activity patterns in adults with severe mental illness[J]. J Nerv Ment Dis, 2005, 193(10):641-646.
[21] Vancampfort D, Firth J, Correll C U, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia:a meta-review of meta-analyses of randomized controlled trials[J]. World Psychiatry, 2019, 18(1):53-66.
[22] Gabriele J M, Dubbert P M, Reeves R R. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain[J]. Obes Rev, 2009, 10(4):442-455.
[23] Daumit G L, Dickerson F B, Wang N Y, et al. A behavioral weight-loss intervention in persons with serious mental illness[J]. N Engl J Med, 2013, 368(17):1594-1602.
[24] Steinberg D, Bennett G G, Svetkey L. The DASH diet, 20 years later[J]. JAMA, 2017, 317(15):1529-1530.
[25] Green C A, Yarborough B J, Leo M C, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications:a randomized trial[J]. Am J Psychiatry, 2015, 172(1):71-81.
[26] Green C A, Yarborough B J, Leo M C, et al. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications[J]. Obesity, 2015, 23(10):1995-2001.
[27] Vancampfort D, Stubbs B, Mitchell A J, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:a systematic review and meta-analysis[J]. World Psychiatry, 2015, 14(3):339-347.
[28] Enez Darcin A, Yalcin Cavus S, Dilbaz N, et al. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings[J]. Schizophr Res, 2015, 166(1-3):201-206.
[29] Centorrino F, Wurtman J J, Duca K A, et al. Weight loss in overweight patients maintained on atypical antipsychotic agents[J]. Int J Obes, 2006, 30(6):1011-1016.
[30] Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain:12-month data on a multimodal weight control program[J]. J Clin Psychiatry, 2004,65(4):471-477
[31] McKibbin C L, Patterson T L, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus:a randomized controlled trial[J]. Schizoph Res, 2006, 86(1-3):36-44.
[32] Bartels S J, Pratt S I, Aschbrenner K A, et al. Clinically significant improved fitness and weight loss among overweight persons with serious mental illness[J]. Psychiatr Servi, 2013, 64(8):729-736.
[33] Zhou F C, Zheng W, Lu L, et al. Prospective memory in schizophrenia:a meta-analysis of comparative studies[J]. Schizophr Res, 2019,pii:S0920-9964(19)30351-2.
[34] Goughari A S, Mazhari S, Pourrahimi A M, et al. Associations between components of metabolic syndrome and cognition in patients with schizophrenia[J]. J Psychiatri Pract, 2015, 21(3):190-197.
[35] 孙岩,赵敏. 精神分裂症心理社会康复:国内研究十年回顾[J]. 精神医学杂志, 2018, 31(3):231-236.
[36] 国家卫生健康委员会. 严重精神障碍管理治疗工作规范(2018年版)[EB/OL].(2018-05-28)[2018-06-08].http://www.nhc.gov.cn/jkj/s7932/201806/90d5fe3b7f48453db9b9beb85dfdc8a8.shtml

对精神分裂症躯体健康问题的生活方式干预

Lifestyle interventions for physical health conditions in patients with schizophrenia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏志燕, 刘薇, 史婷婷. 老年2型糖尿病患者血尿酸浓度与代谢综合征的相关性分析[J]. 首都医科大学学报, 2023, 44(1): 137-142.
[2]	廉思源, 吴涵, 韩金祥, 肖存利, 任艳萍, 金文青, 王雯, 马辛. 影响精神分裂症自我报告康复效果的因素[J]. 首都医科大学学报, 2022, 43(2): 233-238.
[3]	李莉, 刘超猛, 任艳萍, 杨春林, 马辛. 改良电休克治疗首发精神分裂症的研究进展[J]. 首都医科大学学报, 2022, 43(2): 249-253.
[4]	郭城伟, 周娇娇, 冯媛, 杨蕴萍. 精神分裂症患者与正常人自尊水平的对照研究[J]. 首都医科大学学报, 2022, 43(2): 294-298.
[5]	陈溪, 马登磊, 李林. 淫羊藿苷对cuprizone诱导精神分裂症样小鼠模型行为学变化、髓鞘脱失及神经炎性反应的影响[J]. 首都医科大学学报, 2021, 42(5): 761-767.
[6]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[7]	来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.
[8]	宁艳哲, 朱虹, 宋楠, 郑思思, 李自艳, 李佳佳, 马睿, 贾竑晓. 石珍安神颗粒改善精神分裂症前驱期患者认知损害的临床观察[J]. 首都医科大学学报, 2021, 42(3): 404-407.
[9]	仪玉伟, 闫芳, 靳玉宏, 肖存利. 精神分裂症住院患者危险行为的影响因素分析[J]. 首都医科大学学报, 2021, 42(2): 323-327.
[10]	沙莎, 赵希希, 韩传亮, 彭兴, 张培, 董雯, 尹晶晶, 王长明. 精神分裂症静息态下alpha活动和认知水平的相关性[J]. 首都医科大学学报, 2021, 42(1): 117-124.
[11]	张颖, 王若梅, 李刚. 稳定期精神分裂症患者认知功能、情绪管理水平及其影响因素分析[J]. 首都医科大学学报, 2021, 42(1): 143-147.
[12]	闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.
[13]	王延雪, 胡虹英, 李新刚, 鹿星梦, 郜桂菊, 梁洪远, 肖江, 杨涤, 王芳, 韩晓涛. 初治人类免疫缺陷病毒感染者合并代谢综合征及心血管病风险状况及其临床特点分析[J]. 首都医科大学学报, 2020, 41(1): 40-44.
[14]	刘鑫垚, 马超, 贾竑晓. 精神分裂症认知损害动物模型的研究现状[J]. 首都医科大学学报, 2020, 41(1): 50-54.
[15]	马超, 贺毅, 孙作厘, 刘鑫垚, 冯正田, 陈沛, 宁艳哲, 朱虹, 尹冬青, 贾竑晓. 基于16S rRNA技术分析石珍安神汤对脱髓鞘小鼠肠道菌群多样性的影响[J]. 首都医科大学学报, 2020, 41(1): 64-70.